NuView Life Sciences Inc is involved in the discovery, development and commercialization of next-generation diagnostic imaging probes and in-vitro disease specific biomarkers with the ability to detect and locate disease at the earliest stages of development. The firm collaborates with research universities and medical centers and has an active pipeline of promising PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Technology) compounds currently involved in pre FDA trials. Although there have been great advances in the understanding and treatment of cancer, this disease today is largely detected and diagnosed with the same procedures and technology that has been used for generations. The same is true for measuring an individuals response to therapy. These methods are inefficient, painful and expensive. NuView wants to change this and is developing a compelling, innovative way to detect, diagnose and personalize the treatment of cancer.
